Last reviewed 2026-04-20 · How we verify

Dextran 2-(Diethylamino)Ethyl Ether (COLEXTRAN)

Phase 2 active

Dextran 2-(Diethylamino)Ethyl Ether (generic name: COLEXTRAN) is a colextran drug. It is currently in Phase 2 development for Hyperlipidemia.

Colextran works by binding to and removing excess cholesterol from the bloodstream.

Dextran 2-(Diethylamino)Ethyl Ether, also known as Colextran, is a small molecule drug in the colextran class. Its exact mechanism of action is unknown, but it is used to treat Hyperlipidemia. Colextran's commercial status is unclear, and it may be patented or off-patent. As a pharmaceutical professional, it is essential to note that Colextran's safety considerations and pharmacokinetic properties are not well-documented.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	COLEXTRAN
Drug class	colextran
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Imagine Colextran as a magnet that attracts and removes excess cholesterol from the blood, helping to lower cholesterol levels and reduce the risk of heart disease. This process is not fully understood, but it is thought to occur through a combination of Colextran's chemical structure and its interaction with cholesterol molecules in the bloodstream.

Approved indications

Hyperlipidemia

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dextran 2-(Diethylamino)Ethyl Ether CI brief — competitive landscape report
Dextran 2-(Diethylamino)Ethyl Ether updates RSS · CI watch RSS

Frequently asked questions about Dextran 2-(Diethylamino)Ethyl Ether

What is Dextran 2-(Diethylamino)Ethyl Ether?

Dextran 2-(Diethylamino)Ethyl Ether (COLEXTRAN) is a colextran drug, indicated for Hyperlipidemia.

How does Dextran 2-(Diethylamino)Ethyl Ether work?

Colextran works by binding to and removing excess cholesterol from the bloodstream.

What is Dextran 2-(Diethylamino)Ethyl Ether used for?

Dextran 2-(Diethylamino)Ethyl Ether is indicated for Hyperlipidemia.

What is the generic name of Dextran 2-(Diethylamino)Ethyl Ether?

COLEXTRAN is the generic (nonproprietary) name of Dextran 2-(Diethylamino)Ethyl Ether.

What drug class is Dextran 2-(Diethylamino)Ethyl Ether in?

Dextran 2-(Diethylamino)Ethyl Ether belongs to the colextran class. See all colextran drugs at /class/colextran.

What development phase is Dextran 2-(Diethylamino)Ethyl Ether in?

Dextran 2-(Diethylamino)Ethyl Ether is in Phase 2.

Drug class: All colextran drugs
Therapeutic area: All drugs in Metabolic
Indication: Drugs for Hyperlipidemia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing